Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Proceeds provide sufficient funds to extend operations and ongoing trials late into the fourth quarter of 2020Company does not intend to raise additional capital for ninety days following the closing...
-
Specialised Therapeutics receives exclusive license to commercialize rigosertib in Australia and New ZealandOnconova to be eligible to receive up to US $30.4 million in clinical, regulatory, and...
-
The INSPIRE Trial enters the final stage of enrollment after surpassing 90% of the required number of randomized patients in November 2019 Pint Pharma Facilitates Opening of Phase 3 INSPIRE Trial in...
-
NEWTOWN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
-
Genomic Profiling at Study Entry in Patients with Higher Risk Myelodysplastic Syndrome (HR-MDS) Following Hypomethylating (HMA) Failure: Results From the INSPIRE Trial, including RAS and other...
-
NEWTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
-
NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
-
NEWTOWN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
-
NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
-
Knight receives exclusive license to commercialize rigosertib in CanadaOnconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit...